pSivida Corp. PSDV, a specialty pharmaceutical company that
is a leader in the development of sustained release ophthalmic drug
treatments, today announced that it has signed a funded technology evaluation
agreement with a leading global pharmaceutical company. The agreement will
evaluate pSivida's proprietary Durasert™ and Tethadur™ technologies for this
pharmaceutical company's select products in ophthalmology. The Durasert
technology system delivers specific quantities of drugs directly to a target
site in the body at controlled rates for predetermined periods of time ranging
from weeks to months. Tethadur is pSivida's proprietary technology for the
delivery of proteins, peptides and antibodies.
“We are extremely pleased to be working with another global pharmaceutical
company to apply our unique technologies to develop transformational products
in ophthalmology,” said Dr. Paul Ashton, pSivida president and CEO.
pSivida has developed three of the four sustained release devices for retinal
diseases that have been approved in either the US or Europe, the most recent
being ILUVIEN®, partnered with Alimera and approved in multiple EU countries.
Independently, pSivida is developing an injectable, sustained release product
to treat uveitis affecting the back of the eye (posterior uveitis) and an
injectable, bioerodible product to treat glaucoma and ocular hypertension in
collaboration with Pfizer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in